At a glance
ClinicalIndex Comparison RecordN/ACompleted· 12 enrolled
Drug / intervention
Polyethylene Glycol Hydrogeldevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
TraceIT TM Hydrogel Tissue Marker for Patients Receiving Definitive Chemoradiation for Bladder Cancer
In Brief
A clinical study evaluating Polyethylene Glycol Hydrogel for Bladder Carcinoma. Completed, enrolled 12 participants across 1 site.
Detailed Summary
This pilot clinical trial studies how well TracelT hydrogel works in localizing bladder tumors in patients undergoing radiation therapy for bladder cancer. TracelT hydrogel marks the location of a bladder tumor and makes it more visible during imaging tests. Using TracelT hydrogel tissue marker may help doctors learn more about tumor location and altering radiation dosage for bladder cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBladder Carcinoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
First PostedApr 2017
Enrollment StartOct 2017
Primary CompletionJan 2020
Study CompletionMay 2020
TodayJul 2026
First PostedApr 24, 2017
Enrollment StartOct 5, 2017
Primary CompletionJan 1, 2020
Study CompletionMay 18, 2020
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 9.2 years ago
Interventions
Polyethylene Glycol Hydrogeldevice
Given TracelT hydrogel via injection